About: Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
Creator	Beissert, Tim Hutzler, Stefan Sahin, Ugur Boller, Klaus Eberle, Regina Erbar, Stephanie Klamp, Thorsten Bodmer, Bianca Hanauer, Jan Jabulowsky, Robert Mühlebach, Michael Schnotz, Jürgen
Source	PMC
abstract	Recombinant vaccine strain-derived measles virus (MV) is clinically tested both as vaccine platform to protect against other pathogens and as oncolytic virus for tumor treatment. To investigate the potential synergism in anti-tumoral efficacy of oncolytic and vaccine properties, we chose Ovalbumin and an ideal tumor antigen, claudin-6, for pre-clinical proof of concept. To enhance immunogenicity, both antigens were presented by retroviral virus-like particle produced in situ during MV-infection. All recombinant MV revealed normal growths, genetic stability, and proper expression and presentation of both antigens. Potent antigen-specific humoral and cellular immunity were found in immunized MV-susceptible IFNAR(−/−)-CD46Ge mice. These immune responses significantly inhibited metastasis formation or increased therapeutic efficacy compared to control MV in respective novel in vivo tumor models using syngeneic B16-hCD46/mCLDN6 murine melanoma cells. These data indicate the potential of MV to trigger selected tumor antigen-specific immune responses on top of direct tumor lysis for enhanced efficacy.
has issue date	2017-12-04(xsd:dateTime)
bibo:doi	10.1038/s41598-017-16928-8
bibo:pmid	29203786
has license	cc-by
sha1sum (hex)	3ba5a8bec872feebb62f6a1f384690ba1cd63a8b
schema:url	https://doi.org/10.1038/s41598-017-16928-8
resource representing a document's title	Antigen-specific oncolytic MV-based tumor vaccines through presentation of selected tumor-associated antigens on infected cells or virus-like particles
has PubMed Central identifier	PMC5715114
has PubMed identifier	29203786
schema:publication	Sci Rep
resource representing a document's body	covid:3ba5a8bec872feebb62f6a1f384690ba1cd63a8b#body_text
is schema:about of	named entity 'CELLS' named entity 'potential' named entity 'antigens' named entity 'concept' named entity 'TO INVESTIGATE' named entity 'PRESENTED' named entity 'INHIBITED' named entity 'ANTIGEN' named entity 'TUMOR VACCINES' named entity 'SPECIFIC' named entity 'THESE' named entity 'EFFICACY' named entity 'MURINE' named entity 'USING' named entity 'COMPARED' named entity 'CELLULAR IMMUNITY' named entity 'PRESENTATION' named entity 'ANTIGENS' named entity 'INFECTED' named entity 'TUMOR ANTIGEN' named entity 'ANTIGEN' named entity 'B16' named entity 'RETROVIRAL' named entity 'VIRUS-LIKE PARTICLES' named entity 'PRESENTATION' named entity 'ANTIGENS' named entity 'ASSOCIATED' named entity 'IFNAR' named entity 'GROWTHS' named entity 'IMMUNOGENICITY' named entity 'INCREASED' named entity 'PROPERTIES' named entity 'DIRECT' named entity 'IMMUNE RESPONSES' named entity 'ENHANCED' named entity 'ONCOLYTIC' named entity 'LYSIS' named entity 'PROPER' named entity 'PRE-CLINICAL' named entity 'FORMATION' named entity 'IN SITU' named entity 'RECOMBINANT' named entity 'VIRUS-LIKE PARTICLE' named entity 'MICE' named entity 'TUMOR' named entity 'CLAUDIN-6' named entity 'THERAPEUTIC EFFICACY' named entity 'HCD46' named entity 'IN VIVO' named entity 'SYNERGISM' named entity 'INFECTION' named entity 'FOUND' named entity 'REVEALED' named entity 'CHOSE' named entity 'NORMAL' named entity 'POTENTIAL' named entity 'OVALBUMIN' named entity 'PROOF OF CONCEPT' named entity 'NOVEL' named entity 'VACCINE' named entity 'ENHANCE' named entity 'GENETIC STABILITY' named entity 'ONCOLYTIC' named entity 'MELANOMA CELLS' named entity 'SYNGENEIC' named entity 'EXPRESSION' named entity 'IDEAL' named entity 'TUMOR MODELS' named entity 'TRIGGER' named entity 'TO CONTROL'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software